Oculis Holding AG (NASDAQ:OCS – Get Free Report)’s share price was up 7% during mid-day trading on Thursday after Guggenheim upgraded the stock to a strong-buy rating. The company traded as high as $30.25 and last traded at $29.8670. Approximately 372,065 shares changed hands during trading, an increase of 6% from the average daily volume of 349,370 shares. The stock had previously closed at $27.91.
Several other brokerages have also recently issued reports on OCS. Needham & Company LLC increased their target price on shares of Oculis from $40.00 to $46.00 and gave the stock a “buy” rating in a report on Tuesday, May 12th. Wall Street Zen cut shares of Oculis from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Stifel Nicolaus increased their target price on shares of Oculis from $40.00 to $50.00 and gave the stock a “buy” rating in a report on Wednesday, March 4th. JPMorgan Chase & Co. increased their target price on shares of Oculis from $38.00 to $42.00 and gave the stock an “overweight” rating in a report on Monday, May 18th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Oculis in a report on Tuesday, April 21st. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Oculis presently has a consensus rating of “Moderate Buy” and a consensus target price of $49.38.
Read Our Latest Stock Analysis on OCS
Institutional Trading of Oculis
Oculis Trading Down 4.9%
The firm has a market capitalization of $1.71 billion, a PE ratio of -13.85 and a beta of 0.38. The company’s 50-day simple moving average is $27.48 and its 200 day simple moving average is $24.86. The company has a quick ratio of 5.18, a current ratio of 5.18 and a debt-to-equity ratio of 0.01.
Oculis (NASDAQ:OCS – Get Free Report) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.14). The firm had revenue of $0.26 million for the quarter, compared to analysts’ expectations of $0.25 million. Oculis had a negative net margin of 8,460.67% and a negative return on equity of 56.78%. As a group, sell-side analysts expect that Oculis Holding AG will post -2.21 EPS for the current year.
Oculis Company Profile
Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.
Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.
Recommended Stories
- Five stocks we like better than Oculis
- Kiniksa Pharmaceuticals Still Has Room to Run After 100% Rally
- MarketBeat Week in Review – 05/18 – 05/22
- SpaceX IPO: Opportunity? Or the Ultimate Hype Trade?
- CAVA Group’s Stock Looks Delicious After Strong Earnings
Receive News & Ratings for Oculis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculis and related companies with MarketBeat.com's FREE daily email newsletter.
